In 2010 at the age of 59, I had Da Vinci surgery with a Gleason 4+5=9 and PSA of 9. Post surgical biopsy showed all margins clear with no seminal vesicle involvement and Gleason post-op score was changed to a 4+3=7. Subsequent PSA was non-detectable as tested every three months for the first two years. Five years after surgery I started TRT. (Testosterone replacement therapy)
PSA remained non-detectable with no incontinence and an active sex life. In 2019 the cancer suddenly went active again with PSA rising from zero to 2.0 in 18 months. Auxium PET scan revealed two lesions in my seminal vesicles so I started Lupron with Cassodex for six months. After four months, I had 35 Proton treatments targeting seminal vesicles and prostate bed. A few months later when the Lupron wore off, and my testosterone rose, my PSA started rising immediately. A new PSMA scan at UCLA June of 2020 revealed a microscopic lesion in right pelvic bone.
Three treatments of SBRT was used 6/20/2020 without ADT because doctors said it would not be needed on such a small lesion. But right after SBRT treatment my PSA continued to rise monthly from .29 to 4.9 over six months. (It was a slow rise at first but the last two months my PSA skyrocketed from.68 to 4.9). No one could account for the dramatic rise except that during that time I had a severe eColi blood infection treated with IV antibiotics.
New PSMA scan 10/18/2021 indicated two small lesions in my lower spine and one in my hip bone. So I started ADT 10/27/2021 with three treatments of SBRT performed at UCLA 18 days later. Blood work on the day before SBRT showed my PSA had dropped to .070 along with testosterone to almost zero in 17 days. PSA 05/05/2022 was .008 and testosterone <7 ng/dL.
Even after SBRT, we realized that spinal mets means the possibility of lingering rogue cancer cells or micro tumors too small to see on PSMA scans. We hoped that those could be starved with ADT. Dr. Steinberg at UCLA thought that SBRT plus ADT was sufficient. My City of Hope oncologist, Dr. Dorf, continued Orgovyx with 90-day shots of Xgeva. (My hemoglobin immediately dropped to 12.) At the thirteenth month on Orgovyx, PSA began a slow rise indicating castrate resistance.
We briefly added 250mg Zytiga + 5mg prednisone before starting Eclipse trial (LU-177 I&T) in June 2023. Beginning PSA was 3.3 and directly before fourth injection in August, PSA dropped to .25 Unfortunately, after fourth injection PSA was .30 and rising. It should be noted that due to cardiovascular problems I stopped all ADT right before last LU-177 injection and remain off.
After October PSMA scan, Dr. Kishan at UCLA found two of three original small spine lesions remained and then immediately hit them with one SBRT treatment.
Directly after SBRT I started and completed Provenge series. A month later PSA went from 2.0 to 1.77 and currently remains at 1.7
Hemoglobin fluctuates between 9 and 10.6, probably due to the Plutonium LU-177 injections damaging bone marrow. In an attempt to jump start red cell production on 12/27/23 I received an iron infusion which helped a little. Will my bone marrow ever start working again?
I’m not sure if the the SBRT will continue to affect PSA causing it to become non detectable or if it stays the same. We know that Provenge does not affect PSA, yet any PSA level means cancer is somewhere. Plan is for a durable remission with the help of a hematologist overseeing blood work and advising how to fortify my immune system.
Due to cardiovascular problems, going back on ADT is a last resort. What do you guys think?